Vor Biopharma Inc. Earnings Per Share, Basic and Diluted
Vor Biopharma Inc. (VOR) reported Earnings Per Share, Basic and Diluted of -$0.61 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-12
- Vor Biopharma Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.61.
- Vor Biopharma Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.49.
- Vor Biopharma Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.50.
- Vor Biopharma Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.50.
- Vor Biopharma Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.10.
- Vor Biopharma Inc. earnings per share, basic and diluted for fiscal 2020 was -$230.57.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.61 10-Q · filed 2022-05-12 | -$1.10 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$1.60 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.10 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.99 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$1.49 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$2.10 10-K · filed 2022-03-14 |
| 2021-09-30 | -$0.50 10-Q · filed 2021-11-10 | -$1.00 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.62 10-Q · filed 2021-11-10 | -$2.89 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$0.50 10-Q · filed 2021-08-09 | -$1.13 10-Q · filed 2021-08-09 | -$2.58 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$4.37 derived: net income ÷ weighted average shares · filed 2022-08-11 |
| 2021-03-31 | -$0.67 10-Q · filed 2022-05-12 | -$2.90 derived: net income ÷ weighted average shares · filed 2022-05-12 | -$6.15 derived: net income ÷ weighted average shares · filed 2022-05-12 | -$9.69 derived: net income ÷ weighted average shares · filed 2022-05-12 |
| 2020-12-31 | -$54.96 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$115.10 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$172.19 derived: net income ÷ weighted average shares · filed 2022-03-14 | -$230.57 10-K · filed 2022-03-14 |
| 2020-09-30 | -$61.23 10-Q · filed 2021-11-10 | -$118.90 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$177.84 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$56.85 10-Q · filed 2021-08-09 | -$115.83 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$59.06 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |